InterveXion Therapeutics
InterveXion Therapeutics is a privately-held clinical-stage biopharmaceutical company
About InterveXion Therapeutics
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
Company Facts
- Headquarters
- Little Rock
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00001_00010
- Total Funding
- $52,800,000
- Last Funding Type
- grant
- Last Funding Date
- 2021-11-01
- Website
- intervexion.com
Industries & Categories
Addiction Treatment, Biopharma, Biotechnology, Health Care, Pharmaceutical
Social Links
Canonical: https://fsome.com/organization/intervexion-therapeutics-74617 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.